Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDT, Ranibizumab, and Combination for PCV
NCT03459144Completed
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2012
- Primary completion
- Jul 2015
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, open-label trial of ranibizumab and verteporfin in polypoidal choroidal vasculopathy (PCV) (3 arms), sponsored by Sun Yat-sen University. Primary endpoint: Best Corrected Visual Acuity at 12 months. Started Dec 2012; status: completed.
02
Drugs
ranibizumabverteporfin
03
Conditions
polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on NCT03459144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03459144.